RPRX Royalty Pharma plc

Price (delayed)

$51.95

Market cap

$20.16B

P/E Ratio

N/A

Dividend/share

$0.3

EPS

N/A

Enterprise value

$24.42B

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's quick ratio rose by 9% QoQ
RPRX's equity is up by 7% since the previous quarter

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
388.13M
Market cap
$20.16B
Enterprise value
$24.42B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
N/A
EBIT
N/A
EBITDA
N/A
Free cash flow
N/A
Per share
EPS
N/A
Free cash flow per share
N/A
Book value per share
$7.33
Revenue per share
N/A
TBVPS
$43.13
Balance sheet
Total assets
$15.99B
Total liabilities
$6.19B
Debt
$5.81B
Equity
$4.45B
Working capital
$2.51B
Liquidity
Debt to equity
1.31
Current ratio
10.31
Quick ratio
8.2
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
N/A
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
0.58%
DPS
$0.3
Payout ratio
N/A

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
1.37%
1 week
1.33%
1 month
18.47%
1 year
N/A
YTD
3.8%
QTD
3.8%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
N/A
Gross profit
N/A
Operating income
N/A
Net income
N/A
Gross margin
N/A
Net margin
N/A

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
P/E
N/A
P/B
7.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RPRX's equity is up by 7% since the previous quarter

Efficiency

How efficient is Royalty Pharma business performance

Dividends

What is RPRX's dividend
DPS
$0.3
Dividend yield
0.58%
Payout ratio
N/A

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 158% more than its total liabilities
Royalty Pharma's debt is 31% higher than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.